Evaluation of an electrochemiluminescent SARS-CoV-2 antibody assay

Authors:
Lau CS¹, Hoo SP¹, Yew SF¹, Ong SK², Lum LT², Heng PY³, Tan JG³, Wong MS³, Aw TC¹,²,⁴,⁵*

1. Department of Laboratory Medicine, Changi General Hospital, Singapore.
2. Department of Pathology, Sengkang General Hospital, Singapore.
3. Department of Laboratory Medicine, Khoo Teck Puat Hospital, Singapore.
4. Department of Medicine, National University of Singapore, Singapore.
5. Academic Pathology Program, Duke-NUS Medical School, Singapore.

* Corresponding Author

Address: Department of Laboratory Medicine, CHANGI GENERAL HOSPITAL, 2 SIMEI STREET 3, SINGAPORE 529889

E-mail: tarchoon@gmail.com

Phone: +65 – 68504927

Fax: +65 – 64269507

© American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.
ABSTRACT

Background: Little is known about the performance of the Roche novel severe acute respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an extensive evaluation of this fully automated assay on the Cobas e801/e602 immunoassay analysers.

Methods: We assessed the linearity, precision, and throughput of the Roche anti-SARS-CoV-2 assay. Sensitivity was calculated from 349 SARS-CoV-2 polymerase chain reaction (PCR) positive samples; specificity was determined from 715 coronavirus disease 2019 (COVID-19)-naïve samples. We examined cross-reactivity against other antibody positive samples (syphilis, RF, ANA, ds-DNA, influenza, dengue, HBV, HCV) and the anti-SARS-CoV-2 kinetics.

Results: The assay cut-off index (COI) was linear up to 90.8. The inter-assay precision was 2.9% for a negative control (COI=0.1) and 5.1% for a positive control (COI=3.0). Assay time is 18min and results are available 1 minute later; throughput for 300 samples was 76 minutes. Only 1 case positive for HBsAg tested falsely positive; specificity was 99.9%. The assay has a sensitivity of 97.1% 14 days after PCR positivity (POS) and 100% at ≥21 days POS; 48.2% of cases had anti-SARS-CoV-2 within 6 days POS. In 11 subjects in whom serum was available prior to a positive antibody signal (COI ≥1.0) the interval between the last negative and first positive COI (time to “sero-conversion”) on average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the anti-SARS-CoV-2 to plateau.

Conclusion: The Roche anti-SARS-CoV-2 assay shows excellent performance with minimal cross-reactivity from other viral and confounding antibodies. Antibody development and sero-conversion appears quite early.
IMPACT STATEMENT

We provide an extensive evaluation of the SARS-CoV-2 antibody assay on the Cobas e801/e602 immunoassay analyser for COVID-19 testing. The assay has good precision, throughput and linear range, with an excellent specificity, sensitivity, positive and negative predictive values when used ≥14 days post-positive PCR. In 11 subjects in whom serum was available prior to a positive antibody signal, the interval between the last negative and first positive reading (time to “sero-conversion”) on average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the titres to plateau. This lends evidence to the early development of SARS-CoV-2 antibodies.
ABBREVIATIONS

SARS-CoV-2 – Novel severe acute respiratory syndrome coronavirus 2

COVID-19 – Coronavirus disease 2019

Anti-SARS-CoV-2 – SARS-CoV-2 antibody

FDA – Food and Drug Administration

HCV – Hepatitis C

HBV – Hepatitis B

RF – Rheumatoid factor

HCWs – Health care workers

COI – Cut-off index

PCR – Polymerase chain reaction

CV – Inter-assay precision

PPA – Positive percentage agreement

NPA – Negative percentage agreement

POS – Post positive PCR

PPV – Positive predictive value

NPV – Negative predictive value

CDC – Centers for Disease Control and Prevention

PPE – Personal protective equipment

ANA – anti-nuclear antibody

Anti-ds-DNA – double-stranded DNA antibody
INTRODUCTION

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. Coronavirus disease 2019 (COVID-19) can present with a range of symptoms (1, 2) and inflicts a disturbingly higher fatality rate in older patients (0.32% in those aged <60 years vs 6.4% in those aged ≥60 years) (3). Viral testing (nucleic acid) remains the recommended diagnostic test for infection (4, 5). However, its long turn-around time has led to calls for more rapid tests like serology. Antibody testing can act as an indirect marker for infection, help identify patients with prior infection or exposure and can be performed relatively quickly. An immune response can develop (6) as soon as 10-13 days after a COVID-19 infection (7, 8). However, the early rapid point-of-care tests (POCT) for anti-SARS-CoV-2 were fraught with inaccuracy. Roche Diagnostics has developed a SARS-CoV-2 antibody (anti-SARS-CoV-2) assay for use on its electrochemiluminescent-immunoassay analysers for the rapid, continuous testing of large numbers of samples. This assay has been granted emergency use authorization by the US Food and Drug Administration (FDA) (9) for laboratory use in May 2020. Some brief evaluations of this assay have been recently available as editorial letters (10, 11). We describe a more extensive evaluation of the Roche anti-SARS-CoV-2 assay on Cobas immunoassay analysers across 3 institutions in Singapore.

MATERIALS AND METHODS

Study design and participants

We evaluated the Roche anti-SARS-CoV-2 assay in a multi-centre, cross-sectional study that complies with STARD guidelines (see Supplementary table 1). Residual serum samples from cases with suspected or confirmed SARS-CoV-2 infection from April to June 2020 were recruited from 3 institutions in Singapore: Changi General Hospital, Khoo Teck Puat Hospital and Sengkang General Hospital. For evaluating diagnostic sensitivity, excess serum samples from COVID-19 cases testing positive for SARS-CoV-2 by PCR were identified. For sensitivity
analysis of an evolving biomarker like anti-SARS-CoV-2 at different time points in the disease evolution, it is customary to divide subjects by days from onset of symptoms or by days post initial PCR positivity (POS). We elected to use POS rather than onset of symptoms as it is a more objective milestone and precludes confounding issues with patients who maybe asymptomatic or pre-symptomatic. Antibody positive samples [dengue, hepatitis C (HCV), hepatitis B (HBV), syphilis, antinuclear antibody (ANA), double-stranded DNA antibody (anti-ds-DNA), rheumatoid factor (RF)] from ambulatory subjects with no suspicion for COVID-19 or acute respiratory illness were recruited for cross-reactivity analysis. For diagnostic specificity, samples were obtained from consenting healthcare workers (HCWs) with no reported respiratory symptoms, some of whom had received their annual southern hemisphere influenza vaccination 4 weeks prior to testing. All samples were collected in Vacutainer Gel separator plain serum tubes (Becton Dickinson SST tubes with silica clot activator, polymer gel, silicone-coated interior).

Instrumentation and analysis

The Roche anti-SARS-CoV-2 assay is a sandwich immunoassay where biotinylated SARS-CoV-2 specific recombinant antigens and SARS-CoV-2 specific recombinant antigens labelled with ruthenium form a sandwich complex with anti-SARS-CoV-2. Streptavidin-coated microparticles are then added, and the complex becomes bound to a solid phase via interactions between biotin and streptavidin. Once the microparticles are captured onto the electrode surface and unbound substances are washed away, an electrical current at the electrode induces chemiluminescence. When compared to the mean chemiluminescent signal of a calibrator, an anti-SARS-CoV-2 index is derived with a reported cut-off index (COI) of 1.0 for positivity. Initially the assay did not include any quality control (QC) materials and the manufacturer advised laboratories to prepare their own QC materials. A negative control derived from serum samples with a target COI of <0.8 and a positive control derived from serum samples with a target COI of 3-15 was recommended. Laboratories were also encouraged to watch their internal QCs carefully as the preliminary on-board stability of the
reagents was 72 hours. The stated assay specificity in the package insert is 99.8% with a sensitivity of 100% for samples ≥14 days post symptom onset.

The molecular laboratories of all 3 hospitals employed real-time polymerase chain reaction (PCR) test systems that targeted at least 2 viral epitopes of SARS-CoV-2. For serology, Changi and Sengkang hospitals employed the Roche Cobas e801 while Khoo Teck Puat used the Cobas e602 immunoassay analyser. Results from all three hospitals were pooled for sensitivity and specificity analyses while Changi General provided details of the technical analyses (precision, linearity and throughput). Inter-assay precision (CV) was analysed using 5 serum pools (including negative and positive controls prepared as per manufacturer recommendations, and 3 positive serum samples over a range of reactive COI values) run 5 times daily over 5 days, as per the CLSI EP15-A3 protocol (12). Assay linearity was assessed by using a single sample with a high COI and diluting it with a single low COI sample to create a series of concentrations that covered the clinically relevant range of COI. The laboratories at Changi General and Khoo Teck Puat are accredited by the College of American Pathologists.

As the Roche anti-SARS-CoV-2 assay is a qualitative test, its sensitivity can be represented by the positive percentage agreement (PPA) between antibody positivity against all PCR positive patients tested. Conversely, the specificity of the test is represented by the negative percentage agreement (NPA) between antibody negativity against all control subjects. No cases with indeterminate or missing results were used in our study.

To study sero-conversion, we examined SARS-CoV-2 PCR positive subjects with residual sera who were initially non-reactive for anti-SARS-CoV-2 but became reactive later.

Statistical analyses were performed using MedCalc software v19.3.1 (MedCalc, Ostend, Belgium). As this work was part of routine evaluation of new diagnostic assays, it was deemed exempt by our institutional review board.
RESULTS

Participants

415 excess serum samples (from 280 individual patients) that tested positive for SARS-CoV-2 by PCR were identified for sensitivity analysis. 66 of these were residual samples from inpatients not initially suspected of having COVID-19 but who subsequently tested positive for SARS-CoV-2 PCR and were excluded from the sensitivity analysis. For cross-reactivity studies, samples positive for other antibodies included dengue N=74, HCV N=3, HBV N=13, syphilis N=1, ANA N=16, anti-ds-DNA N=4, and RF N=7. Except for dengue, all other samples for cross-reactivity analysis were from excess serum samples from before November 2019.

597 samples from consenting healthy (no self-reported respiratory symptoms) healthcare workers (HCWs) were collected (laboratory staff, nurses, and housekeeping staff, the majority of whom are female), 315 of whom had received their annual southern hemisphere influenza vaccination 4 weeks prior to testing. The patient demographics are displayed in Supplementary table 2.

Precision and linearity

The Roche assay showed good precision, with a CV of 2.9% for negative controls (mean COI = 0.1) and 5.1% for positive controls (mean COI = 3.0) (See Table 1); at higher COI values (9.1, 18.9 and 42.4), the precision was very good (1.4%, 1.5%, 2.0%). The assay COI signal was found to be linear from 1.0 to 90.8 (y = 181.44x – 1.3568) (see Figure 1, Supplementary Table 3) and curvilinear rightwards thereafter.

Throughput

At Changi General the anti-SARS-CoV-2 assay on the Roche Cobas e801 is run using two measuring cells. The Cobas e801 was able to analyse 50 samples in 29 minutes and 100 specimens in 39 minutes. When loaded with 300 samples (and not performing other routine
tests simultaneously), the Cobas e801 completed the sample analysis in 76 minutes (see Supplementary Table 4).

Cross-reactivity

Out of the 315 HCWs who received their annual influenza vaccination 4 weeks prior to testing, none were reactive for anti-SARS-CoV-2. In cases positive for other antibodies (n=118), 117 were negative for anti-SARS-CoV-2, however, 1 case that was positive for HBsAg tested positive (false positive) for anti-SARS-CoV-2 (see Table 2) with a COI of 1.3.

< Table 2 >

Specificity

As there was minimal cross-reactivity with anti-SARS-CoV-2 in the 433 samples above (Table 2), we included them in diagnostic specificity analysis together with the other 282 samples from other HCWs. From these 715 samples, the Roche anti-SARS-CoV-2 assay had a specificity of 99.86% (95% CI 99.22 to 100.00).

Sensitivity

Of the 349 samples used for sensitivity analysis (from 205 individual patients), the PPA increased to 97.1% (95% CI 90.06 to 99.65) after 14 days post positive PCR (POS), and to 100% after 21 days POS (95% CI 90.26 to 100.00) (see Table 3). Notably, 48.2% of patients had positive antibodies within the first week after their PCR diagnosis. Interestingly, of the 66 samples excluded from the sensitivity analyses with late PCR diagnosis (see above), 48.5% were positive for anti-SARS-CoV-2.

< Table 3 >

Positive and negative predictive values

Assuming a disease prevalence of 5%, the predictive value of the Roche anti-SARS-CoV-2 assay (specificity of 99.86% and sensitivity of >97% when used after 14 days POS) will be as
follows: positive predictive value (PPV) 97.34% (95% CI 83.75 to 99.62) and negative predictive value (NPV) 99.85% (95%CI 99.41 to 99.96).

Sero-conversion

Eleven subjects were available for sero-conversion study and the progression of their antibody levels (COI) were plotted against days POS (See Figure 2 and Table 4). Using the manufacturer recommended COI of 1.0 the interval for “sero-conversion” (last negative reading to first positive reading), extrapolated from figure 2, ranged from 1-6 days with an average of 3 days. In 8 of the 11 subjects the antibody levels plateaued over time (1-7 days from positivity, mean of 4 days).

< Figure 2 >

< Table 4 >

DISCUSSION

The Roche anti-SARS-CoV-2 assay shows good precision (CV of 2.9% and 5.1% at COI levels of 0.1 and 3.0) and a linear signal response over a wide COI range (0.98 to 90.8). The diagnostic sensitivity of the assay is 97.1-100.0% ≥14 days POS. The diagnostic specificity is 99.9% in 715 non-COVID-19 samples tested. The PPV was 97.3%, and NPV 99.9% at ≥14 days POS. Our results are in close agreement with the manufacturer’s reported specifications. They are also in agreement with other evaluations of the Roche anti-SARS-CoV-2 assay in the literature (10, 11, 13); the reported assay CV (2.1-4.6%, 1.2-3.6%, <3.9%), test sensitivity at ≥14 days post-onset of symptoms (87.7%, 91.1%, 89.4%) and test specificity (100%, 100%, 98.7%) were similar to ours. This assay easily meets the US Centers for Disease Control and Prevention (CDC) and the FDA requirements for an acceptable SARS-CoV-2 serology test - >90% sensitivity and >95% specificity (14, 15). As the sensitivity/PPA only increases to over 90% after 14 days post PCR positivity, patients should not be tested earlier. This is also
supported by other studies showing that it takes up to 11-14 days before anti-SARS-CoV-2 develop (16). However, serology may have a role when PCR tests are negative in the face of other clinical symptom suggestive of COVID19. This approach has been proposed in a Chinese study (17); using an ELISA IgM they were able to diagnose a family cluster of COVID19 where PCR was negative. The Roche assay has an excellent throughput, analysing 300 samples in 76 minutes. This is a major boon when processing large sample numbers from screening centres.

In our study we have used days POS to categorize our population. As COVID-19 can have asymptomatic and pre-symptomatic patients (18-20), using the presence of symptoms as a pre-selection criterion for inclusion will exclude asymptomatic and pre-symptomatic cases; days POS will mitigate against this. Notably, out of 66 leftover serum samples that were available before COVID-19 was suspected and PCR tested positive, 32 were already positive for anti-SARS-CoV-2. From the 11 patients with multiple longitudinal samples in figure 2, “sero-conversion” (interval between last negative point and first positive point) takes an average of 3 days, and that antibody titres plateau an average of 4 days later. A recent report (8) found that the time course of COVID19 antibodies (both IgG and IgM) tended to plateau in 6 days after they become positive in 19 subjects. Using a Diazyme assay, the median time for IgM seropositivity was 5 days and 4 days for IgG seroconversion (21). Anti-SARS-CoV-2 has also been detected on the first day of PCR positivity (22) or within 7 days of symptom onset in 12.2% of patients (8). This indicates that in some patients, anti-SARS-CoV-2 development can occur earlier than expected.

A recent report (23) found that SARS-CoV-2 infection may cause false-positive dengue antibody results; the clinical presentation of these two conditions may be indistinguishable. It is noteworthy that in patients with positive dengue serology (n = 74) we did not encounter any false positive anti-SARS-CoV-2. Our study also confirms that the assay remains specific even in patients positive for HCV, syphilis, ANA, ds-DNA and RF. Moreover, in 315 samples with post-influenza vaccination, none were positive for anti-SARS-CoV-2, reinforcing the fact that
the Roche assay has little cross-reactivity with other antibodies. We have since encountered one case of HBV with a false positive anti-SARS-CoV-2. It is likely that as we test more samples, cases of false positive serology will emerge. The sero-negativity of most of our HCWs also underscores the adequacy of our personal protective equipment (PPE) measures. The PPE measures taken by hospital staff across institutions in Singapore are similar (24), and include the use of surgical masks in low-risk areas (non-COVID-19 inpatient rooms, afebrile patient zones in the emergency department, non-infectious disease clinics) and N95 respirators/eye protection/gowns/gloves in high-risk areas (COVID-19 isolation rooms, febrile patient zones in the emergency department). However, their lack of antibodies also means that most of these HCWs remain at risk for future COVID-19 infections and they should continue to rigorously enforce safety precautions.

The strength of this evaluation is that it is a multi-center collaborative effort with sufficient sample numbers for sensitivity, specificity, and cross-reactivity analyses. A limitation of our study is that we have relatively fewer samples for cases after 14 days POS. Further studies on larger populations would be desirable. In addition, we do not have the sero-prevalence of SARS-CoV-2 in our community. However, it is to be expected that in areas with low prevalence of COVID-19 (<1%), high false positive rates will be encountered. At the time of this study, we created our own negative and positive control materials from patient sera based on manufacturer recommendations. However, control materials have since been supplied by the manufacturer. The on-board reagent stability of 72 hours in the initial manufacturer information sheet has now been updated to 14 days.

CONCLUSION

Our results show that the Roche anti-SARS-CoV-2 assay has excellent performance and is highly comparable both with the manufacturer’s information and other published studies. With an excellent throughput, the Cobas e801 should be extremely useful in the tracking the spread
of SARS-CoV-2 in various populations and for sero-prevalence studies. We have also found that anti-SARS-CoV-2 can develop early.

ACKNOWLEDGMENTS

We would like to thank Temasek Holdings Pte Ltd for sponsoring the laboratory testing kits used in this study.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

S.F. Yew, statistical analysis.

Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.
Consultant or Advisory Role: None declared.
Stock Ownership: None declared.
Honoraria: T.C. Aw, Abbott Diagnostics, Roche Diagnostics, Beckman-Coulter.
Research Funding: None declared.
Expert Testimony: None declared.
Patents: None declared.

Role of Sponsor: No sponsor was declared.
REFERENCES

(1) Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med 24 April, 2020. [Epub ahead of print] Doi: 10.1056/NEJMcp2009249.

(2) Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 15 May, 2020. [Epub ahead of print] Doi: 10.1056/NEJMcp2009575.

(3) Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet 30 March, 2020. [Epub ahead of print] Doi: https://doi.org/10.1016/S1473-3099(20)30243-7.

(4) Centers for Disease Control and Prevention. Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html. (Accessed 20 June, 2020.)

(5) The Royal College of Pathologists of Australia. Position Statement, COVID19 IgG/IgM Rapid POCT Tests. 2020. https://www.rcpa.edu.au/getattachment/bf9c7996-6467-44e6-81f2-e2e0cd71a4c7/COVID19-IgG-IgM-RAPID-POCT-TESTS.aspx. (Accessed 20 June, 2020.)

(6) U.S. Food and Drug Administration. Important Information on the Use of Serological (Antibody) Tests for COVID-19 - Letter to Health Care Providers. 2020. https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-use-serological-antibody-tests-covid-19-letter-health-care-providers. (Accessed 20 June, 2020.)

(7) Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for 2 detecting antibodies against SARS-CoV2. J Clin Microbiol 30 March, 2020. [Epub ahead of print] Doi: 10.1128/JCM.00461-20.

(8) Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y, et al. Antibody Responses to SARS-CoV-2 in Patients With COVID-19. Nat Med 29 April, 2020. [Epub ahead of print] Doi: 10.1038/s41591-020-0897-1.
(9) United States Food and Drug Administration. May 2, 2020, Tammy Dean, Elecsys Anti-
SARS-CoV-2, Roche Diagnostics. 2020. https://www.fda.gov/media/137602/download.
(Accessed 15 June, 2020.)

(10) Favresse J, Eucher C, Elsen M, Marie TH, Dogne JM, Douxfils J. Clinical performance
of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2
total antibodies. Clin Chem 2 June, 2020. [Epub ahead of print] Doi: https://doi.org/10.1093/clinchem/hvaa131.

(11) Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al.
Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. Clin Chem 2 June, 2020. [Epub ahead of print] Doi: https://doi.org/10.1093/clinchem/hvaa132.

(12) Clinical and Laboratory Standard Institute (CLSI). User Verification of Precision and
Estimation of Bias; Approved Guideline-Third Edition, CLSI document EP15-A3. PA
Wayne; CLSI 2014.

(13) Public Health England. Evaluation of the Roche Elecsys AntiSARS-CoV-2 serology
assay for the detection of anti-SARSCoV-2 antibodies. 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887222/PHE_Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2.pdf.
(Accessed 15 June, 2020.)

(14) Centers for Disease Control and Prevention. Interim Guidelines for COVID-19
Antibody Testing. 2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html. (Accessed 16 June, 2020.)

(15) US Food and Drug Administration. EUA Authorized Serology Test Performance. 2020.
https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-
authorized-serology-test-performance. (Accessed 16 June, 2020.)

(16) Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-
CoV-2 in Patients of Novel Coronavirus Disease 2019. Clin Infect Dis 28 March, 2020.
[Epub ahead of print] Doi: 10.1093/cid/ciaa344.
(17) Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling early humoral response to diagnose novel corona disease (COVID-19). Clin Infect Dis March 21, 2020. [Epub ahead of print] Doi: 10.1093/cid/ciaa310.

(18) Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 12 March, 2020. [Epub ahead of print] Doi: 10.2807/1560-7917.ES.2020.25.10.2000180.

(19) Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 411–415.

(20) Li G, Li W, He X, Cao Y. Asymptomatic and Presymptomatic Infectors: Hidden Sources of COVID-19 Disease. Clin Infect Dis 9 April, 2020. [Epub ahead of print] Doi: 10.1093/cid/ciaa418.

(21) Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. Longitudinal monitoring of SARS-CoV-2 IgM and IgG seropositivity to detect COVID-19. J Appl Lab Med May 19, 2020. [Epub ahead of print] Doi: 10.1093/jalm/jfaa079

(22) Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol 7 May, 2020. [Epub ahead of print] Doi: 10.1128/JCM.00941-20.

(23) Yan G, Lee CK, Lam L, Yan B, Chua YX, Lim A, et al. Covert COVID-19 and false-positive dengue serology in Singapore. Lancet 4 March, 2020. [Epub ahead of print] Doi: https://doi.org/10.1016/S1473-3099(20)30158-4.

(24) Then HL, Lim DW, Kyaw WM, Loh J, Lee LT, Ang B, et al. Responding to the COVID-19 Outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems. Clin Infect Dis 21 April, 2020. [Epub ahead of print] Doi: 10.1093/cid/ciaa468.

16
Table 1: Precision of the Roche anti-SARS-CoV-2 assay

| Pool ID | Pool type               | Min Index | Max Index | Mean Index | SD    | %CV |
|---------|-------------------------|-----------|-----------|------------|-------|-----|
| 1       | Negative control (patient sera) | 0.074     | 0.084     | 0.078      | 0.002 | 2.87|
| 2       | Positive control (patient sera) | 2.770     | 3.280     | 2.991      | 0.153 | 5.11|
| 3       | Sample 1                | 8.840     | 9.260     | 9.065      | 0.129 | 1.43|
| 4       | Sample 2                | 18.200    | 19.400    | 18.856     | 0.277 | 1.47|
| 5       | Sample 3                | 40.700    | 43.700    | 42.444     | 0.850 | 2.00|

Abbreviations: SD: Standard deviation, %CV: Inter-assay precision
Table 2: Cross-reactivity analysis for the Roche anti-SARS-CoV-2 assay.

|                                      | N  | Roche negative | Roche positive |
|--------------------------------------|----|----------------|----------------|
| Recent influenza vaccination          | 315| 315            | 0              |
| Dengue fever                         | 74 | 74             | 0              |
| Hepatitis C                          | 3  | 3              | 0              |
| Hepatitis B*                         | 13 | 12             | 1              |
| Syphilis antibodies                  | 1  | 1              | 0              |
| Anti-nuclear antibodies              | 16 | 16             | 0              |
| Double-stranded DNA antibody         | 4  | 4              | 0              |
| Rheumatoid factor                    | 7  | 7              | 0              |
| Total                                | 433| 432            | 1              |

* Hepatitis B cases included various combinations of HBsAg, anti-HBc IgM, HBeAg and anti-HBe.
Table 3: Roche assay sensitivity (positive percentage agreement) by days post positive PCR.

| Days POS | N  | Antibody positive | Antibody negative | PPA (%) | 95% CI       |
|----------|----|-------------------|-------------------|---------|-------------|
| 0-6      | 189| 91                | 98                | 48.2    | 40.84 to 55.52 |
| 7-13     | 90 | 68                | 22                | 75.6    | 65.36 to 84.00 |
| ≥14      | 70 | 68                | 2                 | 97.1    | 90.06 to 99.65 |
| ≥21      | 36 | 36                | 0                 | 100.0   | 90.26 to 100.00 |

Abbreviations: POS: Post-positive PCR, PPA: Positive percentage agreement, CI: Confidence interval
Table 4: SARS-CoV-2-Ab COI trends in COVID-19 patients with initial COI < 1.0 (by days POS).

| Patient | Days POS | COI  | POS day when COI ≥1.0* | Interval between negative to COI ≥1.0 | POS day of plateau* | Interval to plateau* |
|---------|----------|------|------------------------|--------------------------------------|---------------------|----------------------|
| A       | 0        | 0.08 | 4+                     | 5                                    | 11+                 | 7                    |
|         | 2        | 0.09 |                        |                                      |                     |                      |
|         | 7        | 7.59 |                        |                                      |                     |                      |
|         | 11       | 9.98 |                        |                                      |                     |                      |
| B       | 0        | 0.08 | 2+                     | 3                                    | NA                  | NA                   |
|         | 1        | 0.09 |                        |                                      |                     |                      |
|         | 4        | 6.03 |                        |                                      |                     |                      |
|         | 6        | 21.0 |                        |                                      |                     |                      |
| C       | 1        | 0.09 | 3+                     | 4                                    | 5+                  | 2                    |
|         | 5        | 5.44 |                        |                                      |                     |                      |
|         | 9        | 6.59 |                        |                                      |                     |                      |
|         | 10       | 5.03 |                        |                                      |                     |                      |
| D       | 3        | 0.08 | 9+                     | 2                                    | 12+                 | 3                    |
|         | 7        | 0.09 |                        |                                      |                     |                      |
|         | 8        | 0.12 |                        |                                      |                     |                      |
|         | 10       | 2.49 |                        |                                      |                     |                      |
|         | 12       | 13.8 |                        |                                      |                     |                      |
|         | 14       | 5.86 |                        |                                      |                     |                      |
|         | 17       | 7.19 |                        |                                      |                     |                      |
|         | 19       | 12.2 |                        |                                      |                     |                      |
| E       | 0        | 0.08 | 5+                     | 2                                    | 11+                 | 6                    |
|         | 1        | 0.09 |                        |                                      |                     |                      |
|         | 5        | 0.51 |                        |                                      |                     |                      |
|         | 7        | 2.36 |                        |                                      |                     |                      |
|         | 11       | 12.6 |                        |                                      |                     |                      |
|         | 15       | 13.1 |                        |                                      |                     |                      |
| F       | 4        | 0.08 | 6+                     | 1                                    | 10+                 | 4                    |
|         | 6        | 0.15 |                        |                                      |                     |                      |
|         | 7        | 1.17 |                        |                                      |                     |                      |
|         | 10       | 14.7 |                        |                                      |                     |                      |
|         | 14       | 15.9 |                        |                                      |                     |                      |
|         | 16       | 14.3 |                        |                                      |                     |                      |
| G       | 2        | 0.08 | 15+                    | 6                                    | NA                  | NA                   |
|         | 6        | 0.19 |                        |                                      |                     |                      |
|         | 12       | 0.35 |                        |                                      |                     |                      |
|         | 18       | 2.72 |                        |                                      |                     |                      |
| H       | 0        | 0.07 | 5+                     | 2                                    | 9+                  | 4                    |
|         | 1        | 0.07 |                        |                                      |                     |                      |
|         | 2        | 0.07 |                        |                                      |                     |                      |
|         | 3        | 0.11 |                        |                                      |                     |                      |
|         | 4        | 0.13 |                        |                                      |                     |                      |
|         | 6        | 6.26 |                        |                                      |                     |                      |
|         | 7        | 9.27 |                        |                                      |                     |                      |
|         | 8        | 13.9 |                        |                                      |                     |                      |
|         | 9        | 17.8 |                        |                                      |                     |                      |
|         | 12       | 18.6 |                        |                                      |                     |                      |
|         | 15       | 12.7 |                        |                                      |                     |                      |
|         | 19       | 10.4 |                        |                                      |                     |                      |
| I       | 0        | 0.11 | 2+                     | 4                                    | NA                  | NA                   |
|         | 1        | 0.19 |                        |                                      |                     |                      |
|         | 5        | 7.98 |                        |                                      |                     |                      |
|         | 2        | 0.12 |                        |                                      |                     |                      |
|         | 4        | 0.34 |                        |                                      |                     |                      |
|         | 6        | 10.3 |                        |                                      |                     |                      |
| J | 8  | 27.6 | 4+ | 2 | 8+ | 4 |
|---|----|------|----|---|----|---|
|   | 10 | 26.9 |    |   |    |   |
|   | 13 | 38.5 |    |   |    |   |
| K | 2  | 0.12 | 3+ | 2 | 4+ | 1 |
|   | 4  | 1.99 |    |   |    |   |
|   | 9  | 2.11 |    |   |    |   |
|   | 12 | 1.76 |    |   |    |   |
|   | 14 | 1.59 |    |   |    |   |
|   | 18 | 1.96 |    |   |    |   |
|   | 22 | 4.24 |    |   |    |   |

*Based on interpolation from figure 2.*

Abbreviations: POS: Post-positive PCR, COI: Cut-off index.

Figure 1: Linearity plot of the Roche anti-SARS-CoV-2 assay.

\[ y = 181.44x + 1.3568 \]
Figure 2: SARS-CoV-2-Ab COI kinetics by days POS in patients with initial COI <1.0.

* y-axis is on a semi-logarithmic scale